Logo

Merck Animal Health’s Innovax-ND-H5 Vaccine Gains the EC’s Marketing Authorization for Chickens

Share this
Merck Animal Health

Merck Animal Health’s Innovax-ND-H5 Vaccine Gains the EC’s Marketing Authorization for Chickens

Shots:

  • The EC has granted marketing authorization to the company’s Innovax-ND-H5 vaccine to address avian influenza virus strains of clade 2.3.4.4b in chickens
  • The Innovax-ND-H5 is a single-dose vaccine given in ovo or subcutaneously at one day old to reduce mortality, symptoms and virus excretion from H5-type highly pathogenic Avian Influenza (HPAI)
  • Furthermore, the vaccine produces immunity against Marek’s and Newcastle diseases plus can be administered in addition to its Rispens strain Marek’s disease vaccine, Nobilis Rismavac

Ref: Merck Animal Health | Image: Merck Animal Health

Related News:- Merck Animal Health to Feature Innovative Solutions Focusing Ruminant Health at the World Buiatrics Congress 2024

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions